Who
William J. Federici
Director
Company insider
Files Form 4 as: Director, Stevanato Group S.p.A; Director, Zynerba Pharmaceuticals; Sr. VP & CFO, West Pharmaceutical Services; Director, Nupathe; Director, Synvista Therapeutics.
In numbers
- Trades disclosed
- 234
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $23.2M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 7 Mar 2005
- Last trade
- 15 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 26 Jun 2026 | STVN Stevanato Group S.p.AMedical Devices | SEC FORM 4 Sold | $26K1,493 at $17.09 | filing |
| 15 Jun 2026filed 26 Jun 2026 | STVN Stevanato Group S.p.AMedical Devices | SEC FORM 4 Sold | $26K1,493 at $17.09 | filing |
| 12 Jun 2026filed 26 Jun 2026 | STVN Stevanato Group S.p.AMedical Devices | SEC FORM 4 Code A | —4,975 at $0.00 | filing |
| 12 Jun 2026filed 26 Jun 2026 | STVN Stevanato Group S.p.AMedical Devices | SEC FORM 4 Code A | —4,975 at $0.00 | filing |
| 10 Oct 2023filed 11 Oct 2023 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —34,663 | filing |
| 10 Oct 2023filed 11 Oct 2023 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —71,736 | filing |
| 10 Oct 2023filed 11 Oct 2023 | Zynerba Pharmaceuticals | SEC FORM 4 Code U | —27,954 | filing |
| 10 Oct 2023filed 11 Oct 2023 | Zynerba Pharmaceuticals | SEC FORM 4 Code U | —47,824 | filing |
| 14 Jun 2023filed 15 Jun 2023 | Zynerba Pharmaceuticals | SEC FORM 4 Sold | $40115 at $0.35 | filing |
| 13 Jun 2023filed 15 Jun 2023 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —71,736 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | Zynerba Pharmaceuticals | SEC FORM 4 Code A | —47,824 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —34,663 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Zynerba Pharmaceuticals | SEC FORM 4 Code A | —23,109 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Zynerba Pharmaceuticals | SEC FORM 4 Sold | $4040 at $1.01 | filing |
| 3 Aug 2021filed 5 Aug 2021 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 3 Aug 2021filed 5 Aug 2021 | Zynerba Pharmaceuticals | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 10 Jun 2020filed 11 Jun 2020 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2019filed 13 Jun 2019 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Oct 2018filed 2 Oct 2018 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | $6,8831,334 at $5.16 | filing |
| 2 Jul 2018filed 3 Jul 2018 | Zynerba Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | $6,8831,103 at $6.24 | filing |
News
Stevanato Group S.p.A. (NYSE:STVN) Receives Average Rating of "Moderate Buy" from BrokeragesSTVN · dailypolitical.com · 6 Oct 2026Financial Contrast: Bionano Genomics (NASDAQ:BNGO) and Stevanato Group (NYSE:STVN)STVN · themarketsdaily.com · 6 Oct 2026
0 headlines in the last 90 days name William J. Federici; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.